Niraparib with pembrolizumab for maintenance treatment of advanced non-small-cell lung cancer after platinum-based chemotherapy with pembrolizumab [ID6345]
In development
Reference number: GID-TA11406
Expected publication date: TBC
The company that markets niraparib has informed NICE that it will not provide an evidence submission for the evaluation. In light of this information NICE will suspend this evaluation from its current work programme and the consultation on the draft scope will close early.
Please accept our apologies for any inconvenience.
As this evaluation has been referred to NICE we will continue to monitor any development and will update interested parties if the situation changes.